

Alessandro Morabito

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3027257/alessandro-morabito-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

174
papers

6,315
citations

36
h-index

75
g-index

180
ext. papers

7,404
ext. citations

4.7
avg, IF

5.06
L-index

#	Paper	IF	Citations
174	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 9	22.4	0
173	A Delphi Consensus Approach for the Management of Chronic Pain during and after the COVID-19 Era.. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	3
172	Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	1
171	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 1653-1665	4.4	2
170	Promising Role of Circulating Tumor Cells in the Management of SCLC. <i>Cancers</i> , 2021 , 13,	6.6	1
169	Angiogenesis Inhibitors in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 655316	5.3	6
168	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. <i>BMC Cancer</i> , 2021 , 21, 549	4.8	0
167	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021 , 148, 24-35	7.5	8
166	Risk Analysis in Healthcare Organizations: Methodological Framework and Critical Variables. <i>Risk Management and Healthcare Policy</i> , 2021 , 14, 2897-2911	2.8	4
165	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2021 , 19, 13	8.5	1
164	Surgery in Small-Cell Lung Cancer. <i>Cancers</i> , 2021 , 13,	6.6	4
163	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021 , 37, 100940	11.3	5
162	RET Inhibitors in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
161	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 . <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2209-2221	7.4	32
160	The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 775-783	4.1	1
159	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020 , 21, 498-508.e2	4.9	27
158	Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications. <i>Translational Lung Cancer Research</i> , 2020 , 9, 61-70	4.4	6

157	Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer 2020 , 1, 117-130		
156	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation 2020 , 8,		29
155	Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
154	Clinical trials and drug cost savings for Italian health service. <i>BMC Health Services Research</i> , 2020 , 20, 1089	2.9	3
153	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists 2020 , 8,		4
152	Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. <i>Future Oncology</i> , 2020 , 16, 2799-2808	3.6	23
151	Immunotherapy in Small Cell Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	19
150	Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls. <i>Cancers</i> , 2020 , 12,	6.6	13
149	Pembrolizumab in lung cancer: current evidence and future perspectives. <i>Future Oncology</i> , 2019 , 15, 3327-3336	3.6	4
148	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib. <i>Cancers</i> , 2019 , 11,	6.6	4
147	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , 2019 , 133, 62-68	5.9	1
146	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 924-937	21.7	562
145	The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Cancers</i> , 2019 , 11,	6.6	27
144	Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. <i>Future Oncology</i> , 2019 , 15, 2905-2914	3.6	52
143	Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF- β 1 and miRNA21 cooperation. <i>PLoS ONE</i> , 2019 , 14, e0219597	3.7	16
142	EGFR Mutations 2019 , 477-486		2
141	The role of circulating free DNA in the management of NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 19-28	3.5	17
140	Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. <i>PLoS ONE</i> , 2019 , 14, e0210330	3.7	3

139	Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study. <i>Journal of Pain Research</i> , 2019 , 12, 117-125	2.9	5
138	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , 2018 , 19, 93-104	4.9	31
137	Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the panacea for all patients?. <i>BMC Medicine</i> , 2018 , 16, 24	11.4	8
136	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 1189-1197	13.4	39
135	Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2585-2592 ²⁷	2.2	27
134	Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. <i>Future Oncology</i> , 2018 , 14, 2861-2874	3.6	75
133	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial. <i>Lung Cancer</i> , 2017 , 108, 15-21	5.9	7
132	Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: Cytological smears versus cell blocks. <i>Cancer Cytopathology</i> , 2017 , 125, 303-312	3.9	16
131	Evaluation of the VeriStrat serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. <i>Lung Cancer</i> , 2017 , 109, 101-108	5.9	24
130	New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 109, 35-41	7	12
129	P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S2217-S2218	8.9	3
128	Angiogenesis Inhibitors in NSCLC. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	41
127	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017 , 8, 57528-57536	3.3	7
126	Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 97, 143-51	7	22
125	BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. <i>Lung Cancer</i> , 2016 , 95, 73-81 ^{5.9}	5.9	14
124	A new look at the ALK gene in cancer: copy number gain and amplification. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 493-502	3.5	17
123	Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. <i>Oncotarget</i> , 2016 , 7, 66595-66605	3.3	67
122	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016 , 99, 31-7	5.9	25

121	Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016 , 24, e86-e88	1.9	2
120	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016 , 17, 461-465	4.9	27
119	Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires (Terra dei Fuochi) of Southern Italy. <i>Anticancer Research</i> , 2016 , 36, 2119-24	2.3	4
118	Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. <i>Clinical Lung Cancer</i> , 2015 , 16, 322-7	4.9	36
117	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 897-907	21.7	314
116	Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. <i>Pharmacogenomics</i> , 2015 , 16, 1135-48	2.6	26
115	Lungs on Fire. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1376	8.9	
114	EGFR mutations in lung cancer: from tissue testing to liquid biopsy. <i>Future Oncology</i> , 2015 , 11, 1611-23	3.6	70
113	Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 910-5	2.2	262
112	Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma. <i>PLoS ONE</i> , 2015 , 10, e0139264	3.7	18
111	Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2014 , 15, 166-70	4.9	24
110	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1379-88	21.7	103
109	Vandetanib as a potential treatment for breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 1295-303	5.9	8
108	Treatment of small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 91, 257-70	7	49
107	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <i>Journal of Translational Medicine</i> , 2014 , 12, 291	8.5	28
106	CD90 expression in atypical meningiomas and meningioma metastasis. <i>American Journal of Clinical Pathology</i> , 2014 , 141, 841-9	1.9	10
105	Prognostic value of circulating tumor cells reduction in patients with extensive small-cell lung cancer. <i>Lung Cancer</i> , 2014 , 85, 314-9	5.9	50
104	Validation of the new IASLC/ATS/ERS lung adenocarcinoma classification: a surgeon's perspective. <i>Journal of Thoracic Disease</i> , 2014 , 6, S547-51	2.6	1

103	Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better□ <i>Current Pharmaceutical Design</i> , 2014 , 20, 3901-13	3.3	6
102	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 1207-18	3.5	10
101	Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 407-20	3.5	14
100	Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. <i>Lung Cancer</i> , 2013 , 81, 77-83	5.9	36
99	Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. <i>Cancer Treatment Reviews</i> , 2013 , 39, 466-72	14.4	51
98	Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. <i>BioMed Research International</i> , 2013 , 2013, 385087	3	27
97	Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e59-60	8.9	14
96	ZEPHYR: failure of a "spring wind" in lung cancer. <i>Translational Lung Cancer Research</i> , 2013 , 2, E4-6	4.4	
95	Integrated therapeutic approaches in the treatment of locally advanced non-small cell lung cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013 , 13, 844-51	2.2	2
94	Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1830-1844	8.9	17
93	Prognostic evaluation and choice of second-line treatment for patients with advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2012 , 1, 55-62	2.6	1
92	Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 233-42	8.9	4
91	Induction therapy for lung cancer: sailing across the pillars of Hercules. <i>Thoracic Surgery Clinics</i> , 2012 , 22, 67-75, vi	3.1	1
90	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3002-11	2.2	193
89	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. <i>Lung Cancer</i> , 2012 , 76, 457-64	5.9	14
88	Cetuximab in non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 163-75	3.5	16
87	Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. <i>Annals of Oncology</i> , 2012 , 23, 2027-2033	10.3	18
86	Bevacizumab in non small cell lung cancer: development, current status and issues. <i>Current Medicinal Chemistry</i> , 2012 , 19, 961-71	4.3	17

85	Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib. <i>Journal of Thoracic Oncology</i> , 2012 , 7, e27-8	8.9	8
84	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2011 , 4, 1-9	2.1	2
83	Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. <i>BMC Cancer</i> , 2011 , 11, 75	4.8	12
82	Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3628-35	2.2	149
81	Gefitinib in non small cell lung cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2011 , 2011, 815269		14
80	Time spent for activation of non-profit studies in oncology in Italy. <i>PLoS ONE</i> , 2010 , 5, e11864	3.7	3
79	Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. <i>Cancer Biology and Therapy</i> , 2010 , 10, 543-8	4.6	43
78	Vinorelbine for non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 493-510	4.1	10
77	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <i>Lung Cancer</i> , 2010 , 67, 86-92	5.9	19
76	Methodological aspects of lung cancer clinical trials in the era of targeted agents. <i>Lung Cancer</i> , 2010 , 67, 127-35	5.9	26
75	Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. <i>European Journal of Cancer</i> , 2010 , 46, 735-43	7.5	60
74	New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1503-14	5.9	8
73	Vandetanib: An overview of its clinical development in NSCLC and other tumors. <i>Drugs of Today</i> , 2010 , 46, 683-98	2.5	24
72	Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1836-43	2.2	137
71	Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. <i>Oncology</i> , 2009 , 76, 49-54	3.6	26
70	Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. <i>Oncologist</i> , 2009 , 14, 378-90	5.7	152
69	Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBEO trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3192-7	2.2	68
68	Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?. <i>Journal of Clinical Oncology</i> , 2009 , 27, e123; author reply e124-5	2.2	2

67	Target-based therapies in breast cancer: current status and future perspectives. <i>Endocrine-Related Cancer</i> , 2009 , 16, 675-702	5.7	47
66	Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 71, 233-41	7	27
65	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 1021-7	3.5	8
64	Systemic treatment of gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 70, 216-34	7	23
63	Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. <i>Lung Cancer</i> , 2009 , 63, 251-8	5.9	26
62	Integration of Target-Based Agents in Current Protocols of Breast Cancer Therapy 2009 , 203-224		
61	Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. <i>BMC Cancer</i> , 2008 , 8, 252	4.8	36
60	Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. <i>Lung Cancer</i> , 2008 , 60, 452-4	5.9	15
59	The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients. <i>Lung Cancer</i> , 2008 , 61, 67-72	5.9	11
58	Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 79-85	1.6	7
57	Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 264-70	2.2	32
56	Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 66, 171-80	7	19
55	Single agent vs combination chemotherapy (CT) as second-line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data of five randomized trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 8052-8052	2.2	3
54	Is human hepatocellular carcinoma a hormone-responsive tumor?. <i>World Journal of Gastroenterology</i> , 2008 , 14, 1682-9	5.6	37
53	Chemotherapy for Metastatic Breast Cancer Patients Who Received Adjuvant Anthracyclines (An Overview) 2008 , 395-414		
52	Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. <i>BMC Cancer</i> , 2007 , 7, 50	4.8	22
51	Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007 , 101, 355-65	4.4	115
50	Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4663-9	2.2	70

49	Methodological Issues of Clinical Research with EGFR Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 292-302	0.4	3
48	First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment. <i>Oncologist</i> , 2007 , 12, 1288-98	5.7	10
47	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology</i> , 2007 , 8, 500-12	21.7	80
46	Methodology of clinical trials with new molecular-targeted agents: where do we stand?. <i>Annals of Oncology</i> , 2006 , 17 Suppl 7, vii128-31	10.3	21
45	Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. <i>British Journal of Cancer</i> , 2006 , 94, 1233-6	8.7	26
44	Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. <i>Oncologist</i> , 2006 , 11, 753-64	5.7	221
43	Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. <i>Oncology Reports</i> , 2006 , 16, 393	3.5	1
42	Is tailored therapy feasible in oncology?. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 57, 79-101	7	16
41	Hormonal treatment of human hepatocellular carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1089, 252-61	6.5	25
40	Multiorganic dissemination of a colorectal signet ring cell carcinoma with fulminant clinical course. <i>International Journal of Gastrointestinal Cancer</i> , 2006 , 37, 49-54		3
39	Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2005 , 11, 248-51	2.2	5
38	Clinical benefit of intermittent administration of imatinib in a patient with metastatic gastrointestinal stromal tumour. <i>Clinical Oncology</i> , 2005 , 17, 96-7	2.8	1
37	Failure of a cetuximab/bevacizumab schedule in a patient with metastatic desmoplastic small round-cell tumour refractory to chemotherapy. <i>Clinical Oncology</i> , 2005 , 17, 393-4	2.8	
36	Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. <i>Oncologist</i> , 2005 , 10, 710-7	5.7	20
35	Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6865-72	2.2	394
34	Therapy of breast cancer with molecular targeting agents. <i>Annals of Oncology</i> , 2005 , 16 Suppl 4, iv28-36	10.3	35
33	Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2004 , 86, 249-57	4.4	22
32	Antiangiogenic strategies, compounds, and early clinical results in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 49, 91-107	7	33

31	Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. <i>Lung Cancer</i> , 2004 , 43, 83-91	5.9	51
30	Phase II study of celecoxib and weekly paclitaxel in the treatment of pretreated advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2004 , 22, 7337-7337	2.2	2
29	Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. <i>Oncology Reports</i> , 2004 , 11, 93-5	3.5	14
28	The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study. <i>Breast Cancer Research and Treatment</i> , 2003 , 78, 29-36	4.4	22
27	Prognostic and predictive indicators in operable breast cancer. <i>Clinical Breast Cancer</i> , 2003 , 3, 381-90	3	28
26	Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. <i>Lancet Oncology, The</i> , 2003 , 4, 605-15	21.7	291
25	Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer. <i>Oncology</i> , 2002 , 63, 205-12	3.6	8
24	Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. <i>Oncology</i> , 2001 , 60, 72-80	3.6	33
23	Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2001 , 65, 71-5	4.4	34
22	Behaviour of metastasis in relation to vascular index in patients with node-positive breast cancer treated with adjuvant tamoxifen. <i>Clinical and Experimental Metastasis</i> , 2000 , 18, 15-20	4.7	4
21	Clinical Management of a Case of Recurrent Apocrine Gland Carcinoma of the Scalp: Efficacy of a Chemotherapy Schedule with Methotrexate and Bleomycin. <i>Tumori</i> , 2000 , 86, 472-474	1.7	18
20	A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , 1999 , 10, 1377-9	10.3	36
19	A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. <i>Oncology</i> , 1999 , 56, 267-73	3.6	3
18	Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. <i>Cancer Journal From Scientific American</i> , 1999 , 5, 101-11		60
17	Tailored therapy for aggressive non-Hodgkin's lymphoma: results of a phase II study with a long-term follow-up. <i>International Journal of Oncology</i> , 1998 , 13, 121-7	1	
16	Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer 1997 , 11, 175		
15	Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis. <i>International Journal of Oncology</i> , 1996 , 8, 827-32	1	5
14	Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes?. <i>European Journal of Cancer</i> , 1996 , 32A, 41-6	7.5	8

13	High-dose recombinant interleukin-2/verapamil combination in advanced cancer. <i>European Journal of Cancer</i> , 1996 , 32A, 1436-7	7.5	4
12	c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2702-8	2.2	332
11	CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). <i>British Journal of Cancer</i> , 1995 , 71, 1283-7	8.7	26
10	Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. <i>American Journal of Kidney Diseases</i> , 1995 , 26, 27-33	7.4	27
9	Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. <i>Oncology</i> , 1995 , 52, 272-7	3.6	37
8	First-line systemic therapy for metastatic breast cancer and management of pleural effusion. <i>Annals of Oncology</i> , 1995 , 6, 1033-43	10.3	8
7	The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. <i>Cancer</i> , 1995 , 76, 1772-8	6.4	141
6	Cytosine arabinoside (Ara-C) plus alpha-interferon (alpha IFN) determine prolonged complete remissions in patients with aggressive non-Hodgkin's lymphoma partially responsive to first-line doxorubicin-containing regimens. <i>British Journal of Haematology</i> , 1994 , 88, 421-3	4.5	10
5	High dose chemotherapy with epirubicin (E) and cyclophosphamide (C) plus hemopoietic colony stimulating factors in locally advanced (LABC) or metastatic (MBC) breast cancer. A phase III trial. <i>European Journal of Cancer</i> , 1993 , 29, S57	7.5	2
4	Low-dose dopamine induces early recovery of recombinant interleukin-2--impaired renal function. <i>European Journal of Cancer</i> , 1993 , 29A, 1119-22	7.5	19
3	Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. <i>Cancer</i> , 1975 , 35, 1108-15	6.4	108
2	Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations. <i>Global & Regional Health Technology Assessment</i> , 9 , 22-29	0.2	
1	Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. <i>Oncology Reports</i> ,	3.5	2